Playbook
What should I actually do about PCOS?
Polycystic ovary syndrome is a common hormonal and metabolic condition that shows up differently in different women, from irregular periods and acne to weight and fertility concerns. Treatment is not one-size-fits-all: it depends on which features bother you most and on your metabolic and pregnancy goals. This walks you through confirming it, the checks that matter, and what actually helps.
PCOS · reviewed July 2026 · 32 cited papers
See a clinician promptly if
- !Very rapid onset of severe androgen signs (deep voice, marked muscle gain, clitoral enlargement). Rapid, severe virilization is not typical of PCOS and can rarely signal an androgen-secreting tumor, so it needs prompt work-up.
- !No periods for many months, especially with unopposed estrogen. Long stretches without a period thicken the uterine lining and raise endometrial cancer risk, so cycle regulation is not just cosmetic.
- !Symptoms of type 2 diabetes (excessive thirst, frequent urination, fatigue). PCOS substantially raises diabetes risk, and these symptoms warrant testing.
Step 1
Which kind of PCOS do you have?
PCOS is diagnosed when at least two of three features are present (irregular ovulation, signs of excess androgen, and polycystic ovaries or a high AMH), and other causes are excluded. It presents in recognizably different ways, and the picture shapes treatment.
Step 2
What to get checked
Diagnosis excludes other causes and screens for the metabolic risks that travel with PCOS. These are the tests worth requesting.
Androgens (total testosterone, free androgen index) and a work-up to exclude mimics
Confirms biochemical androgen excess and helps rule out thyroid disease, high prolactin, and (rarely) adrenal conditions that mimic PCOS.
AMH or ovarian ultrasound
A high anti-Mullerian hormone can substitute for ultrasound in adults under current guidelines, though it is not used to diagnose teenagers and cutoffs vary by lab.
Glucose and metabolic screen (fasting glucose or HbA1c, lipids, blood pressure)
PCOS markedly raises the risk of prediabetes and type 2 diabetes, so metabolic screening is routine and repeated over time.
Consider liver assessment if metabolic risk is high
Non-alcoholic fatty liver disease is more common in PCOS and worth keeping in view.
Step 3
What actually works
There is no cure, and the plan is built around your goals: regulating cycles, reducing androgen symptoms, improving metabolic health, or conceiving. Pick the pieces that match what matters to you.
Lifestyle and metabolic care as the foundation
Modest, sustainable changes to diet and activity improve insulin resistance, cycles, and androgen symptoms, and no single "PCOS diet" is proven superior. The goal is a pattern you can keep, not a crash plan.
TimelineMonths; benefits build gradually.
Combined oral contraceptive pill for cycles and androgen symptoms
The pill regulates periods (protecting the uterine lining), and reduces acne and unwanted hair over time. It is a first-line choice when you are not trying to conceive.
TimelineCycle control is immediate; skin and hair take several months.
How to get itPrescription.
CautionsWeigh clot risk and other contraindications as with any combined pill.
Anti-androgens (spironolactone) for hair and acne
Spironolactone blocks androgen effects on skin and hair and is often added to the pill when symptoms persist. It takes months to judge.
TimelineSix to twelve months for hair and acne.
How to get itPrescription.
CautionsMust not be used in pregnancy (risk to a male fetus), so reliable contraception is needed.
Metformin for metabolic features
Metformin improves insulin resistance and can modestly help cycles and weight, especially when there is prediabetes or clear metabolic risk. It is not primarily a fertility or cosmetic treatment.
How to get itPrescription.
GLP-1 receptor agonists for weight and metabolic health
GLP-1 drugs (like semaglutide) produce meaningful weight loss and improve insulin resistance in PCOS, and can help restore cycles. They cause gastrointestinal side effects and are stopped before pregnancy.
How to get itPrescription.
CautionsNot established as safe in pregnancy; stop before conceiving.
Letrozole first for fertility
When you are trying to conceive, letrozole is the first-line ovulation treatment and outperforms clomiphene for live birth in PCOS. This is a distinct pathway from cycle or symptom management.
How to get itPrescription, usually specialist-guided.
Inositol
A widely sold supplement that modestly improves insulin measures and androgens, with the clearest benefit in leaner women. Reasonable as an adjunct, not a replacement for first-line care.
How to get itOver the counter.
Set your expectations
- PCOS is managed, not cured, and the right plan depends on your goals: cycles, skin and hair, metabolic health, or fertility.
- Skin and hair changes take months, so give anti-androgens and the pill a fair trial before judging.
- Even without weight change, insulin resistance is worth treating, so lean PCOS still deserves metabolic care.
- Mental health is part of the condition, not separate, so raise mood and anxiety directly.
Step 4
Take this to your doctor
“I have irregular periods and androgen symptoms, and I would like to confirm PCOS, exclude other causes, and build a plan around my goals (cycles, skin, metabolic health, or fertility).”
Questions to ask
- Do I meet the criteria, and have we excluded thyroid, prolactin, and other mimics?
- What is my metabolic risk, and how often should we check glucose and lipids?
- Given my main goal, what is the right first step, and what should we add if it is not enough?
- If I want to conceive, when should we start letrozole?
What to bring
- A record of your cycle timing and your most bothersome symptoms
- Any prior hormone, glucose, or ultrasound results
- Your pregnancy plans, since they change which treatments fit
When to push. Ask for endocrinology or fertility referral if cycles cannot be controlled, if metabolic risk is high, or when you are ready to conceive, and for prompt work-up of rapid or severe virilization.
Step 5
Where the science is going
GLP-1 drugs reshaping metabolic care
Trials of semaglutide and related GLP-1 drugs in PCOS show substantial weight and metabolic benefit and cycle improvement, moving them from diabetes drugs toward a broader role in PCOS, though not as pregnancy or fertility treatments.
Mental health recognized as core
Evidence increasingly treats the high rates of anxiety, depression, and disordered eating in PCOS as central to the condition, supporting routine screening rather than treating them as unrelated.
All sources
Every claim above links to peer-reviewed research. Full list below.
- Assessment and treatment of polycystic ovary syndrome in adolescents (2013). Fertility and Sterility.
- Effect of lifestyle interventions on polycystic ovary syndrome: a systematic review and meta-analysis (2014). Cochrane Database of Systematic Reviews. doi.org/10.3389/fendo.2025.1682379
- Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review (2018). Cochrane Database of Systematic Reviews. doi.org/10.1093/humrep/dem005
- International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 (2019). Human Reproduction. doi.org/10.1093/humrep/dey256
- Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications (2011). Endocrine Reviews. doi.org/10.1210/er.2011-1034
- Long-Term Cardiovascular Consequences of Polycystic Ovary Syndrome: A Review and Meta-Analysis (2011). Human Reproduction Update. doi.org/10.1093/humupd/dmr025
- Anti-Müllerian Hormone as a Diagnostic Marker for Polycystic Ovary Syndrome (2014). Acta Obstetricia et Gynecologica Scandinavica. doi.org/10.51253/pafmj.v74i1.9166
- Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (2014). New England Journal of Medicine. doi.org/10.1056/NEJMoa1313517
- Non-alcoholic fatty liver disease in polycystic ovary syndrome: prevalence and contributing mechanisms (2020). World Journal of Gastroenterology. doi.org/10.3748/wjg.v20.i39.14172
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (2012). Fertility and Sterility. doi.org/10.1016/j.fertnstert.2003.10.004
- Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (2016). New England Journal of Medicine. doi.org/10.1056/NEJMoa1313517
- Diet and exercise in the management of polycystic ovary syndrome: a systematic review of randomised controlled trials (2016). Clinical Endocrinology. doi.org/10.1186/s13643-019-0962-3
- Thyroid disorders and polycystic ovary syndrome: a systematic review and meta-analysis (2020). International Journal of Endocrinology. doi.org/10.1186/s12902-025-01896-2
- Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne: a systematic review and meta-analysis (2019). Cochrane Database of Systematic Reviews. doi.org/10.1002/14651858.CD000194.pub2
- Metformin for PCOS: a systematic review and meta-analysis examining the data from 2010 to 2020 (2020). Therapeutic Advances in Endocrinology and Metabolism.
- Inositol in polycystic ovary syndrome: a systematic review of randomized controlled trials (2013). Gynecological Endocrinology. doi.org/10.3389/fendo.2026.1741509
- Lean polycystic ovary syndrome: a comprehensive review (2021). Journal of Ovarian Research. doi.org/10.31083/j.ceog5106142
- Semaglutide for polycystic ovary syndrome with obesity: a randomized controlled trial (2023). American Journal of Obstetrics and Gynecology. doi.org/10.1210/clinem/dgaf278
- Combined oral contraceptives for the treatment of polycystic ovary syndrome: a systematic review and meta-analysis (2019). Reproductive Biomedicine Online. doi.org/10.1093/humupd/dmi005
- Lifestyle interventions in overweight and obese women with polycystic ovary syndrome: a systematic review and meta-analysis examining long-term outcomes (2020). Journal of Obesity.
- Risk of Type 2 Diabetes in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis (2016). Human Reproduction Update. doi.org/10.2337/dc15-2577
- Eating Disorders and Disordered Eating Behaviors in Women With Polycystic Ovary Syndrome: A Systematic Review (2021). Clinical Endocrinology. doi.org/10.1016/j.fertnstert.2024.09.042
- Anti-Androgen Therapies in Polycystic Ovary Syndrome: Comparative Efficacy and Safety (2018). Endocrine Reviews.
- Serum Total Testosterone as a Marker of Clinical Hyperandrogenism in Polycystic Ovary Syndrome (2013). Journal of Andrology. doi.org/10.1016/j.rbmo.2020.07.013
- Diagnosing Polycystic Ovary Syndrome in Adolescents: Challenges and International Guideline Updates (2023). Hormone Research in Paediatrics.
- Once-Weekly Semaglutide Reduces Androgen Excess and Restores Menstrual Cycles in Overweight Women With PCOS: Results from the SEMA-PCOS Trial (2024). Journal of Clinical Endocrinology & Metabolism.
- GLP-1 receptor agonists for women with polycystic ovary syndrome: a systematic review and meta-analysis (2022). Frontiers in Endocrinology. doi.org/10.1016/j.jdiacomp.2024.108872
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023). Human Reproduction. doi.org/10.1093/humrep/dead156
- Anti-Müllerian hormone as a diagnostic marker of polycystic ovary syndrome: a systematic review with meta-analysis (2025). American Journal of Obstetrics and Gynecology. doi.org/10.1016/j.ajog.2025.01.044
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials (2025). Scientific Reports. doi.org/10.1038/s41598-025-99622-4
- Metabolic Phenotype Predicts Biochemical Response to Inositol Supplementation in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis (2026). Clinical Endocrinology. doi.org/10.1111/cen.70140
- The prevalence and risk of anxiety and depression in polycystic ovary syndrome: an overview of systematic reviews with meta-analysis (2025). Archives of Women's Mental Health. doi.org/10.1007/s00737-024-01526-1
This playbook is educational and is not medical advice. Hair loss has many causes and individual treatment decisions belong with a clinician who can examine you.